Regulus Therapeutics Inc. (RGLS) financial statements (2021 and earlier)
Company profile
| Business Address |
10628 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 34 | 15 | 20 | 10 | 14 | 21 | 33 | ||
| Cash and cash equivalents | 34 | 15 | 20 | 10 | 14 | 14 | 13 | ||
| Short-term investments | 6 | 19 | |||||||
| Prepaid expense | 4 | 4 | 4 | 4 | 4 | 4 | 5 | ||
| Other current assets | 0 | 1 | 1 | 1 | 2 | ||||
| Other undisclosed current assets | 2 | 1 | 0 | 3 | 1 | 0 | 0 | ||
| Total current assets: | 40 | 20 | 24 | 18 | 19 | 25 | 39 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | 1 | 1 | 2 | 8 | 8 | 9 | ||
| Intangible assets, net (including goodwill) | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||
| Intangible assets, net (excluding goodwill) | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||
| Other noncurrent assets | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Total noncurrent assets: | 2 | 2 | 1 | 2 | 9 | 9 | 10 | ||
| TOTAL ASSETS: | 42 | 21 | 26 | 20 | 28 | 35 | 49 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4 | 4 | 4 | 6 | 7 | 4 | 9 | ||
| Accounts payable | 1 | 2 | 2 | 3 | 2 | 1 | 5 | ||
| Accrued liabilities | 1 | 1 | 1 | 2 | 4 | 2 | 2 | ||
| Employee-related liabilities | 2 | 1 | 1 | 2 | 2 | 1 | 1 | ||
| Deferred revenue | 0 | 0 | ✕ | ✕ | ✕ | ||||
| Debt | 15 | 15 | 15 | 15 | 17 | 19 | 20 | ||
| Contract with customer, liability | ✕ | ✕ | 0 | 0 | 3 | 0 | |||
| Other liabilities | 3 | 3 | 2 | 3 | 2 | 2 | |||
| Total current liabilities: | 22 | 21 | 20 | 25 | 27 | 26 | 31 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 0 | 1 | 0 | 1 | 0 | 0 | 0 | ||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | 0 | 0 | 0 | ||
| Other liabilities | 0 | 1 | 0 | 1 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent liabilities | 7 | 7 | 7 | ||||||
| Total noncurrent liabilities: | 0 | 1 | 0 | 1 | 7 | 8 | 8 | ||
| Total liabilities: | 22 | 22 | 21 | 26 | 34 | 33 | 39 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 20 | (0) | 5 | (6) | (6) | 2 | 10 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Additional paid in capital | 431 | 406 | 406 | 390 | 387 | 386 | 384 | ||
| Accumulated other comprehensive loss | (0) | (0) | |||||||
| Accumulated deficit | (411) | (406) | (401) | (396) | (393) | (384) | (374) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | ||||||||
| Total stockholders' equity: | 20 | (0) | 5 | (6) | (6) | 2 | 10 | ||
| TOTAL LIABILITIES AND EQUITY: | 42 | 21 | 26 | 20 | 28 | 35 | 49 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 0 | 0 | 0 | 7 | 0 | 0 | 0 | |
| Operating expenses | (4) | (5) | (5) | (10) | (8) | (10) | (13) | |
| Operating loss: | (4) | (5) | (5) | (3) | (8) | (10) | (13) | |
| Interest and debt expense | (1) | (1) | (1) | (1) | (0) | (1) | (1) | |
| Loss from continuing operations before equity method investments, income taxes: | (5) | (6) | (5) | (3) | (8) | (10) | (14) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 0 | 0 | 0 | 0 | (0) | 0 | 0 | |
| Loss from continuing operations before income taxes: | (5) | (5) | (5) | (3) | (9) | (10) | (14) | |
| Income tax expense | (0) | |||||||
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net loss available to common stockholders, diluted: | (5) | (5) | (5) | (3) | (9) | (10) | (14) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (5) | (5) | (5) | (3) | (9) | (10) | (14) | |
| Comprehensive loss: | (5) | (5) | (5) | (3) | (9) | (10) | (14) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (0) | 0 | 0 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (5) | (5) | (5) | (3) | (9) | (10) | (14) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.